Phosphate binders in patients with chronic kidney disease

SUMMARY

Hyperphosphataemia in patients with chronic kidney disease, particularly those on dialysis, can be ameliorated by oral phosphate binders in conjunction with dietary phosphate restriction.

Although phosphate binders reduce serum phosphate in these patients, it remains uncertain whether they improve clinical outcomes.

Calcium-based binders are frequently used, but their popularity is waning due to emerging evidence of accelerated vascular calcification.

The use of aluminium-based binders has been limited by a perceived risk of aluminium accumulation.

The non-calcium-based phosphate binders – sevelamer hydrochloride, lanthanum carbonate and sucroferric oxyhydroxide – have become available and subsidised by the Pharmaceutical Benefits Scheme for patients on dialysis.

The pill burden and adverse effects (particularly gastrointestinal intolerance) associated with phosphate binders often contribute to poor medication adherence.

Introduction

Hyperphosphataemia is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) and is due to impaired phosphate excretion by the kidney.\(^1\)\(^-\)\(^3\)

It is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to lower serum phosphate by reducing intestinal absorption of dietary phosphate. Hyperphosphataemia is normally asymptomatic. However, phosphate binders may provide symptomatic relief from pruritus and red irritated eyes, which are more commonly reported in patients with serum phosphate elevations greater than 1.8 mmol/L.\(^4\)\(^,\)\(^5\)

Phosphate binders are a commonly prescribed class of drug for patients on dialysis. In Australia, the annual expense for phosphate binders has increased significantly since sevelamer hydrochloride and lanthanum carbonate were included on the Pharmaceutical Benefits Scheme (PBS), with the mean pill cost increasing from $12.85 to $59.85 per patient per week.\(^6\) There is a lack of trial evidence for both benefit in patients and cost-effectiveness of phosphate lowering.\(^7\) Phosphate binders may also account for up to 50% of the daily pill burden in patients with chronic kidney disease.\(^8\) Together with frequent adverse drug effects (particularly gastrointestinal intolerance), this contributes to poor medication adherence.\(^9\)

Phosphate binders

There are three main types of phosphate binders available – calcium-containing binders and aluminium-containing binders, which have been around for many years and are cheap, and the new non-calcium-based binders (sevelamer, lanthanum and sucroferric oxyhydroxide) which are considerably more expensive (see Table).\(^1\)\(^-\)\(^3\)

Calcium carbonate is the most common form of phosphate binder prescribed, particularly in non-dialysis chronic kidney disease. It is typically given to patients with advanced chronic kidney disease, including those receiving dialysis. As with all phosphate binders, calcium-based binders are most effective when taken with meals (which also limits calcium absorption).\(^10\) They should be prescribed in conjunction with moderate dietary phosphate restriction, ideally supervised by an accredited practising dietitian. Phosphate-rich foods with a high phosphate to protein ratio (processed foods, fast foods and cola drinks) are best avoided, while foods with a high biologic value (e.g. meats and eggs) should be retained to maintain nutritional status.\(^11\)\(^,\)\(^12\)

Aluminium-based binders are a second-line drug in non-dialysis chronic kidney disease. The other newer non-calcium-based binders – sevelamer, lanthanum and sucroferric oxyhydroxide – are only available under the PBS for dialysis patients.
### Characteristics of oral phosphate binders available in Australia

<table>
<thead>
<tr>
<th>Phosphate binders</th>
<th>Mechanism of action</th>
<th>Form, strength</th>
<th>Initial dose</th>
<th>Maximum recommended dose</th>
<th>Cost per tablet</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aluminium hydroxide</td>
<td>Forms insoluble phosphate complexes in the gut</td>
<td>600 mg tablets</td>
<td>1 tablet</td>
<td>2 tablets</td>
<td>20 cents</td>
<td>Inexpensive, calcium-free</td>
<td>No safe dose established, significant adverse effects (e.g. potential central nervous system toxicity, megaloblastic anaemia, osteomalacia, gastrointestinal upset), requires regular monitoring of serum aluminium</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>Forms insoluble phosphate complexes in the gut</td>
<td>Chewable tablets, 500 mg, 600 mg elemental calcium</td>
<td>1 tablet</td>
<td>1 tablet</td>
<td>17 cents</td>
<td>Moderately effective, relatively inexpensive</td>
<td>Hypercalcaemia, large doses required to be effective, possible vascular calcification, unpalatable</td>
</tr>
<tr>
<td>Sevelamer hydrochloride</td>
<td>An anion exchange resin</td>
<td>800 mg tablets</td>
<td>1-3 tablets a day with meals</td>
<td>0.3 g/kg/day</td>
<td>$1.72</td>
<td>Calcium-free, lipid-lowering effect</td>
<td>Expensive, high pill burden, gastrointestinal adverse effects (bloating)</td>
</tr>
<tr>
<td>Lanthanum carbonate</td>
<td>Forms insoluble phosphate complexes in the gut</td>
<td>500 mg, 750 mg, 1000 mg chewable tablets</td>
<td>500-750 mg 3 times a day with meals</td>
<td>1000 mg 3 times a day with meals</td>
<td>500 mg $2.91, 750 mg $4.39, 1000 mg $4.94</td>
<td>Low pill burden, high efficacy, works in wide range of pH, no negative changes on bone histology</td>
<td>Expensive, gastrointestinal adverse effects, uncertain long-term effects</td>
</tr>
<tr>
<td>Sucroferric oxyhydroxide</td>
<td>A ligand exchange iron-based compound</td>
<td>500 mg chewable tablets</td>
<td>1 tablet</td>
<td>6 tablets per day</td>
<td>$4.19</td>
<td>Low pill burden, works in wide range of pH, minimal systemic absorption</td>
<td>Expensive, gastrointestinal adverse effects (stool discoloration)</td>
</tr>
</tbody>
</table>

For all binders except lanthanum and sucroferric oxyhydroxide, the starting dose is typically 1–2 tablets three times daily with each meal, depending on potency. Between-meal snacks are often covered with half a tablet. For calcium-based binders and sevelamer, the dose can be increased to a maximum of six or more tablets daily. Other medicines should be given separately as phosphate binders can interfere with the absorption of drugs such as oral iron and ciprofloxacin.

**Calcium-containing phosphate binders**

Calcium binders have historically been an appealing first choice, because they also address the hypocalcaemia that is often seen with hyperphosphataemia in patients with chronic kidney disease. However, hypercalcaemia and accelerated vascular calcification are the main concerns with calcium-containing phosphate binders, particularly when they are combined with vitamin D therapy.

The Kidney Disease Outcomes Quality Initiative Guidelines suggest that doses should not exceed 1500 mg/day of elemental calcium, based on evidence that this produces a positive calcium balance (excess body stores of calcium leading to soft-tissue and vessel calcification) in chronic kidney disease. However, there is little evidence of patient outcomes to support this recommendation. Another common adverse effect of these drugs is gastrointestinal upset, particularly constipation. The other main advantage of calcium-based binders is that they are inexpensive.

**Aluminium-containing phosphate binders**

Aluminium hydroxide has an excellent phosphate-binding capacity and has been used for over three decades. A number of (principally US-based) guidelines advise against long-term use of aluminium-based binders because of concerns about aluminium intoxication (dementia, osteomalacia, anaemia). This is despite little evidence of toxicity with these
drugs in an era of ultrapure dialysis water quality.\textsuperscript{22} Some European countries as well as Australia still use aluminium for this purpose but regular testing of dialysis water is mandatory if aluminium is to be used orally. Also, oral citrate must be avoided in patients taking aluminium binders as this has been shown to lead to enhanced absorption and cases of neurological toxicity.\textsuperscript{23} There are a limited number of small randomised trials examining the efficacy and safety of aluminium as a binder. However, they were inadequately powered for examining patient-level outcomes.\textsuperscript{24-29}

**Sevelamer hydrochloride**

Sevelamer is the most commonly prescribed non-calcium-based phosphate binder, but has a lower phosphate-binding capacity than other phosphate binders. Its off-target effects include lowering serum low-density lipoprotein cholesterol and increasing the concentrations of fetuin-A (calcification inhibitor).\textsuperscript{30} However, these effects have not been shown to improve cardiovascular outcomes for dialysis patients in prospective trials. The primary disadvantages of this drug are its high price and high pill burden. It may also reduce the bioavailability of fat-soluble vitamins. Its main adverse effects are gastrointestinal intolerance and metabolic acidosis.\textsuperscript{31}

**Lanthanum carbonate**

Lanthanum is a trivalent metal phosphate binder which has a similar affinity for phosphate as aluminium-based drugs.\textsuperscript{32} It is roughly twice as potent as calcium and sevelamer. Lanthanum powder is more effective than chewable tablets\textsuperscript{33,34} and reduces the pill burden.\textsuperscript{35} It is also the only oral phosphate binder to come in three different tablet strengths, meaning the maximum number of tablets per day is always three. Despite poor intestinal absorption, lanthanum may deposit in tissues, particularly liver and bone.\textsuperscript{36} However, in studies with extended follow-up there is no evidence of clinical hepatotoxicity\textsuperscript{37} and bone toxicity.\textsuperscript{38,39} Like other phosphate binders, lanthanum may cause gastrointestinal intolerance, particularly nausea. Similarly to sevelamer, this drug is expensive.

**Sucroferric oxyhydroxide**

Sucroferric oxyhydroxide is now registered in Australia as an iron-based phosphate binder for patients with chronic kidney disease on dialysis. Phosphate binding occurs across a wide range of stomach pH, with a peak at pH 2.5.\textsuperscript{40} Common adverse effects include diarrhoea and change in stool colour. There was no evidence of iron accumulation in a phase III extension study.\textsuperscript{41,42} The binder has a similar pill burden to lanthanum carbonate, as it is given as one pill with each meal and is easily chewable, which may improve patient adherence.\textsuperscript{43} The cost of sucroferric oxyhydroxide is similar to lanthanum and sevelamer.

**Other phosphate binders**

A number of other drugs have been used as phosphate binders, including sevelamer carbonate,\textsuperscript{44} calcium acetate,\textsuperscript{45} magnesium carbonate,\textsuperscript{46} ferric citrate,\textsuperscript{47} colestilan,\textsuperscript{48} bixalomer\textsuperscript{49} and nicotinic acid\textsuperscript{50} but are not registered in Australia for this purpose.

**How effective are phosphate binders in chronic kidney disease?**

Despite evidence that phosphate binders reduce serum phosphate, a recent Cochrane review involving 7631 participants from 60 studies found no convincing evidence for improvements in all-cause or cardiovascular mortality, vascular calcification or fracture risk.\textsuperscript{51} Calcium-based binders were associated with significantly lower serum phosphate (mean difference 0.07 mmol/L) when compared with sevelamer. However, sevelamer was associated with a lower risk of hypercalcaemia (risk ratio 0.45, 95% CI\textsuperscript{*} 0.35–0.59) and a higher risk of adverse gastrointestinal events (risk ratio 1.58, 95% CI 1.11–1.25). There was no difference in all-cause mortality between calcium-based binders and sevelamer.\textsuperscript{51}

A meta-analysis of 11 randomised, controlled trials found that patients treated with non-calcium-based binders had a 22% decreased risk of all-cause mortality (risk ratio 0.78, 95% CI 0.61–0.98) compared with patients treated with calcium-based binders.\textsuperscript{52} However, the results were limited by moderate trial heterogeneity. No significant benefit of non-calcium-based binders was evident in large trials, or after correcting for publication bias or removing a trial with a high risk of bias.\textsuperscript{53,54}

A recent meta-analysis of phosphate binders reported that no phosphate binder reduced mortality compared to placebo in adults with chronic kidney disease.\textsuperscript{55} More importantly, sevelamer resulted in lower mortality than calcium-based drugs, while the comparative effects of lanthanum, iron-based drugs and colestilan were less certain.\textsuperscript{56} Phosphate binders therefore effectively reduce serum phosphate in patients with chronic kidney disease, but it is uncertain whether they improve clinical outcomes. There may be a mortality difference between calcium-based and non-calcium-based binders, but it is not

\textsuperscript{*} confidence interval
Phosphate binders in patients with chronic kidney disease

clear if this reflects a harmful effect of calcium-based binders, a beneficial effect of non-calcium-based binders or both.

This raises the economic argument of cost-effectiveness. The older binders such as calcium carbonate and aluminium hydroxide are cheaper (a few cents per tablet) than the newer binders sevelamer, lanthanum and sucroferric oxyhydroxide (see Table). This makes use of the newer binders potentially harder to justify.\(^4,5\)

**Guidelines**

Based on poor quality and conflicting evidence, guidelines make weak suggestions that oral phosphate binders should be used for hyperphosphataemia-complicating chronic kidney disease to maintain serum phosphate in the normal range.\(^2\) They also suggest that calcium-based binders should be dose restricted (or avoided) in the following circumstances:
- the presence of hypercalcaemia
- arterial calcification
- adynamic bone disease (a low bone turnover condition) or serum parathyroid hormone concentrations that are less than two times the upper limit of the laboratory reference range.\(^6\)

Long-term use of aluminium-based binders is advised against because of the potential risk of toxicity. The Kidney Health Australia guidelines – Caring for Australasians with Renal Impairment (KHA-CARI) – recommend that phosphate binders are effective in reducing serum phosphate in advanced kidney disease.\(^5\) Calcium salt-based binders are recommended as first-line drugs but their use should be minimised when serum calcium is above the target range (2.4 mmol/L) or serum parathyroid hormone is below the upper limit of the reference range.\(^5\)

**Conclusion**

Oral phosphate binders are widely used for hyperphosphataemia in patients with advanced chronic kidney disease, although it remains uncertain whether they improve patient outcomes such as renal bone disease, cardiovascular events and mortality. Calcium carbonate is the most commonly used phosphate binder, but clinicians are increasingly prescribing the more expensive, non-calcium-based phosphate binders, particularly sevelamer.\(^5\) This is primarily because emerging evidence suggests calcium-based binders may accelerate vascular calcification and cardiovascular mortality.

If a phosphate binder is prescribed, choice will be influenced by whether or not the patient is on dialysis because non-calcium binders (lanthanum carbonate, sevelamer hydrochloride and sucroferric oxyhydroxide) are not available on the PBS for non-dialysis patients. Cost, comitant conditions, pill burden and patient tolerance should also be considered (see Fig.). Prescription should be accompanied by dietary advice, patient education and regular assessment of adherence.

\(^4\) The desired parathyroid hormone concentration in chronic kidney disease is more than two times the upper limit of normal. If it is less than this, the patient may be at risk of adynamic bone disease.
REFERENCES


